Steven M. Fruchtman - Aug 2, 2023 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role
PRESIDENT, CHIEF EXECUTIVE OFF, Director
Signature
/s/ Mark Guerin, Attorney-in-Fact
Stock symbol
ONTX
Transactions as of
Aug 2, 2023
Transactions value $
-$4,791
Form type
4
Date filed
8/4/2023, 04:42 PM
Previous filing
Mar 14, 2023
Next filing
Feb 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONTX Common Stock Options Exercise +12.6K +31.05% 53K Aug 2, 2023 Direct F1
transaction ONTX Common Stock Tax liability -$4.79K -4.74K -8.94% $1.01 48.3K Aug 3, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONTX Restricted Stock Units Options Exercise $0 -12.6K -50% $0.00 12.6K Aug 2, 2023 Common Stock 12.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On August 2, 2021 the reporting person was granted 37,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.